Search results for "roe"

showing 10 items of 9822 documents

Fatal Liver and Bone Marrow Toxicity by Combination Treatment of Dichloroacetate and Artesunate in a Glioblastoma Multiforme Patient: Case Report and…

2016

A 52-year-old male patient was treated with standard radiochemotherapy with temozolomide for glioblastoma multiforme (GBM). After worsening of his clinical condition, further tumor-specific treatment was unlikely to be successful, and the patient seeked help from an alternative practitioner, who administered a combination of dichloroacetate (DCA) and artesunate (ART). A few days later, the patient showed clinical and laboratory signs of liver damage and bone marrow toxicity (leukopenia, thrombocytopenia). Despite successful restoration of laboratory parameters upon symptomatic treatment, the patient died 10 days after the infusion. DCA bears a well-documented hepatotoxic risk, while ART can…

0301 basic medicineCancer Researchmedicine.medical_specialtymedicine.medical_treatmentCase ReportToxicologychemotherapyGastroenterologylcsh:RC254-28203 medical and health scienceschemistry.chemical_compound0302 clinical medicineMedizinische FakultätInternal medicineadverse effectmedicineddc:610Adverse effectCancerLiver injuryChemotherapyLeukopeniaTemozolomidebusiness.industrymedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSurgeryClinical trial030104 developmental biologychemistryOncologyArtesunate030220 oncology & carcinogenesisadverse side effectsErythropoiesismedicine.symptombusinessmedicine.drugcomplementary and alternative medicine
researchProduct

Abstract P1-19-46: A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (…

2020

Abstract Background: Dysregulation of the PI3K/AKT/mTOR signaling pathway occurs in solid tumor malignancies. GDC-0077 (G) is a potent p110α-selective, p110α-mutant degrading inhibitor with anti-tumor activity in PIK3CA-mutant breast cancer xenograft models as a single agent and in combination with endocrine therapies (ET) with or without a CDK4/6 inhibitor (i). An open-label, Phase I dose escalation study of Galone and in combination with ET and P is underway in patients (pts) with locally advanced or metastatic PIK3CA-mutant solid tumors. Data from the combinations of G and L with and without P in pts with PIK3CA-mutant HR+/HER2- breast cancer are presented herein. Methods: This study (NC…

0301 basic medicineCancer Researchmedicine.medical_specialtymedicine.medical_treatmentmacromolecular substancesPalbociclibNeutropeniaGastroenterology03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicineotorhinolaryngologic diseasesmedicineDexamethasoneChemotherapybusiness.industryLetrozolemedicine.diseaseHypokalemia030104 developmental biologyOncology030220 oncology & carcinogenesisPharmacodynamicsmedicine.symptombusinessmedicine.drugCancer Research
researchProduct

Modulation of CD4 T Cell Response According to Tumor Cytokine Microenvironment

2021

Simple Summary It is now accepted that CD4 T lymphocytes play an essential role in the anti-tumor response. CD4 T lymphocytes can activate and regulate several aspects of innate and adaptive immunity and participate in the rejection of tumors. Understanding the impact of the tumor, through cytokines present in the microenvironment, but also the effect of anti-cancer therapies are critical aspects of immunotherapy research aiming at improving the anti-tumor response dependent on CD4 T lymphocytes. Abstract The advancement of knowledge on tumor biology over the past decades has demonstrated a close link between tumor cells and cells of the immune system. In this context, cytokines have a majo…

0301 basic medicineCancer Researchmedicine.medical_treatmentContext (language use)ReviewBiologylcsh:RC254-28203 medical and health sciences0302 clinical medicineImmune systemmedicinecancerTumor microenvironmentImmunotherapyAcquired immune systemlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPhenotypeCD4cytokines030104 developmental biologyCytokineOncology030220 oncology & carcinogenesisCancer researchimmunotherapyHomeostasisCancers
researchProduct

Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma

2018

The advent of immune checkpoint (ICP) blockade has introduced an unprecedented paradigm shift in the treatment of cancer. Though very promising, there is still a substantial proportion of patients who do not respond or develop resistance to ICP blockade. In vitro and in vivo models are eagerly needed to identify mechanisms to maximize the immune potency of ICP blockade and overcome primary and acquired resistance to ICP blockade. Vγ9Vδ2 T cells isolated from the bone marrow (BM) from multiple myeloma (MM) are excellent tools to investigate the mechanisms of resistance to PD-1 blockade and to decipher the network of mutual interactions between PD-1 and the immune suppressive tumor microenvir…

0301 basic medicineCancer Researchmedicine.medical_treatmentMini Reviewlcsh:RC254-28203 medical and health sciences0302 clinical medicineImmune systemIn vivoMedicinetumor vaccinationVg9Vd2 T cells immune checkpoint blockade immunotherapy tumor vaccination multiple myelomaMultiple myelomaTumor microenvironmentVg9Vd2 T cellsbusiness.industryImmunotherapyimmune checkpoint blockadelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseVγ9Vδ2 T cellsImmune checkpointBlockademultiple myeloma030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer researchBone marrowimmunotherapybusinessFrontiers in Oncology
researchProduct

Tumor Microenvironment And Epithelial Mesenchymal Transition As Targets To Overcome Tumor Multidrug Resistance

2020

It is well established that multifactorial drug resistance hinders successful cancer treatment. Tumor cell interactions with the tumor microenvironment (TME) are crucial in epithelial-mesenchymal transition (EMT) and multidrug resistance (MDR). TME-induced factors secreted by cancer cells and cancer-associated fibroblasts (CAFs) create an inflammatory microenvironment by recruiting immune cells. CD11b+/Gr-1+ myeloid-derived suppressor cells (MDSCs) and inflammatory tumor associated macrophages (TAMs) are main immune cell types which further enhance chronic inflammation. Chronic inflammation nurtures tumor-initiating/cancer stem-like cells (CSCs), induces both EMT and MDR leading to tumor re…

0301 basic medicineCancer Researchmedicine.medical_treatmentMultidrug resistanceTargeted therapyTargeted therapy0302 clinical medicineCancer-Associated FibroblastsNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsTumor-Associated MacrophagesTumor MicroenvironmentPharmacology (medical)HypoxiaTOR Serine-Threonine KinasesSmall moleculesChemotherapy ; Hypoxia ; Inflammation ; Microenvironment ; Multidrug resistance ; Small molecules ; Targeted therapy.Drug Resistance Multiple3. Good healthDNA DemethylationGene Expression Regulation NeoplasticInfectious DiseasesOncology030220 oncology & carcinogenesisInflammation MediatorsEpithelial-Mesenchymal TransitionStromal cellMicroenvironmentBiologyProinflammatory cytokine03 medical and health sciencesCell Line TumormedicineAnimalsHumansChemotherapyEpithelial–mesenchymal transitionPharmacologyInflammationTumor microenvironmentCancerHypoxia-Inducible Factor 1 alpha Subunitmedicine.diseaseHistone Deacetylase InhibitorsMultiple drug resistanceDisease Models Animal030104 developmental biologyDrug Resistance NeoplasmCancer cellCancer research
researchProduct

The Functional Crosstalk between Myeloid-Derived Suppressor Cells and Regulatory T Cells within the Immunosuppressive Tumor Microenvironment

2021

Simple Summary Immunotherapy improved the therapeutic landscape for patients with advanced cancer diseases. However, many patients do not benefit from immunotherapy. The bidirectional crosstalk between myeloid-derived suppressor cells (MDSC) and regulatory T cells (Treg) contributes to immune evasion, limiting the success of immunotherapy by checkpoint inhibitors. This review aims to outline the current knowledge of the role and the immunosuppressive properties of MDSC and Treg within the tumor microenvironment (TME). Furthermore, we will discuss the importance of the functional crosstalk between MDSC and Treg for immunosuppression, issuing particularly the role of cell adhesion molecules. …

0301 basic medicineCancer Researchmedicine.medical_treatmentT cellCellReviewBiologylcsh:RC254-282regulatory T cellscrosstalk03 medical and health sciencestumor immune evasion0302 clinical medicinecell–cell contactmedicinetumor microenvironmentReceptorCD18Tumor microenvironmentCell adhesion moleculeImmunotherapylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmyeloid-derived suppressor cells<b>Keywords: </b>myeloid-derived suppressor cellsCrosstalk (biology)030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisβ2 integrinsMyeloid-derived Suppressor CellCancer researchimmunotherapyCD11Cancers
researchProduct

Role of Hypoxia and the Adenosine System in Immune Evasion and Prognosis of Patients with Brain Metastases of Melanoma: A Multiplex Whole Slide Immun…

2020

Simple Summary The introduction of immune-checkpoint inhibitors improved the therapeutic landscape for patients with advanced malignant melanoma. However, many patients, including patients with melanoma brain metastases, do not derive benefit from immune-checkpoint blockade. Hence, biomarkers are needed to identify potential mechanisms of resistance and optimize patient selection. This study aimed to explore the role of hypoxia-mediated immunosuppression within the tumor microenvironment of patients with metastatic melanoma using multiplex immunofluorescence. We analyzed the prognostic relevance of the hypoxia surrogate marker GLUT-1, the adenosine-synthesizing ectoenzymes CD73/CD39, and th…

0301 basic medicineCancer Researchmultiplex immunohistochemistrymedicine.medical_treatmentimmune checkpoint inhibitorIpilimumablcsh:RC254-282Articlespatial statistics03 medical and health sciences0302 clinical medicineImmune systemmedicineCytotoxic T celltumor microenvironmentipilimumabradiotherapyTumor microenvironmentimmunosuppressionbusiness.industryhypoxiaMelanomaImmunosuppressionmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCTL*030104 developmental biologyOncologyadenosine030220 oncology & carcinogenesisCancer researchbusinessCD8medicine.drugCancers
researchProduct

Determination of meropenem in endotracheal tubes by in-tube solid phase microextraction coupled to capillary liquid chromatography with diode array d…

2017

Meropenem is a widely used antimicrobial for the treatment of infections associated with the use of invasive medical devices in intensive care unit patients. These treatments are not always effective, in fact, in-vitro studies have demonstrated the difficulty of antimicrobials to penetrate into the biofilm, however in-vivo studies of the effect of these compounds is a trend, mostly because of the complexity of pulmonary samples extracted from ETTs. Therefore, the objective of this study was to evaluate in-tube solid phase microextraction (in-tube SPME) coupled to capillary liquid chromatography (CapLC) with DAD to determine meropenem in Errs in order to estimate the penetration capability i…

0301 basic medicineCapillary action030106 microbiologyClinical BiochemistryPharmaceutical ScienceEndotracheal tubesengineering.materialSolid-phase microextraction01 natural sciencesMeropenemAnalytical Chemistry03 medical and health sciencesCapillary columnCoatingCapillary ElectrochromatographyLimit of DetectionCapillary-LC-DADDrug DiscoverymedicineIntubation IntratrachealHumansSpectroscopySolid Phase MicroextractionChromatographyChemistryBiofilm010401 analytical chemistryIn-tube SPMEPenetration (firestop)MeropenemDiode array0104 chemical sciencesAnti-Bacterial AgentsCapillary lengthengineeringThienamycinsmedicine.drugChromatography LiquidJournal of pharmaceutical and biomedical analysis
researchProduct

Innate Sensing through Mesenchymal TLR4/MyD88 Signals Promotes Spontaneous Intestinal Tumorigenesis

2019

Summary MyD88, an adaptor molecule downstream of innate pathways, plays a significant tumor-promoting role in sporadic intestinal carcinogenesis of the Apcmin/+ model, which carries a mutation in the Apc gene. Here, we show that deletion of MyD88 in intestinal mesenchymal cells (IMCs) significantly reduces tumorigenesis in this model. This phenotype is associated with decreased epithelial cell proliferation, altered inflammatory and tumorigenic immune cell infiltration, and modified gene expression similar to complete MyD88 knockout mice. Genetic deletion of TLR4, but not interleukin-1 receptor (IL-1R), in IMCs led to altered molecular profiles and reduction of intestinal tumors similar to …

0301 basic medicineCarcinogenesisBiologymedicine.disease_causeArticleGeneral Biochemistry Genetics and Molecular BiologyExtracellular matrixMice03 medical and health sciences0302 clinical medicinemedicinetumor microenvironmentAnimalsHumansReceptorinnate immunityTumor microenvironmentInnate immune systemMesenchymal stem cellCell biologyIntestinesToll-Like Receptor 4030104 developmental biologyMyeloid Differentiation Factor 88Knockout mouseTLR4Carcinogenesiscancer-associated fibroblasts030217 neurology & neurosurgerySignal Transduction
researchProduct

The Role of Transforming Growth Factor-β in Human Hepatocarcinogenesis: Mechanistic and Therapeutic Implications From an Integrative Multiomics Appro…

2017

0301 basic medicineCarcinoma HepatocellularHepatologyLiver NeoplasmsGastroenterologyTransforming growth factor betaBiologyArticleCell biology03 medical and health sciences030104 developmental biologyTransforming Growth Factor betaTransforming Growth Factorsbiology.proteinHumansReceptors Transforming Growth Factor betaTransforming growth factorGastroenterology
researchProduct